Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer

Ye,Sujuan; Yang,Weihan; Wang,Yu; Ou,Wenjing; Ma,Qingping; Yu,Chuanjiang; Ren,Jiang; Zhong,Guoxing; Shi,Huashan; Yuan,Zhu; Su,Xiaolan; Zhu,Wen

doi:10.3892/ijmm.2012.1171

Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer

Authors:
- Sujuan Ye
- Weihan Yang
- Yu Wang
- Wenjing Ou
- Qingping Ma
- Chuanjiang Yu
- Jiang Ren
- Guoxing Zhong
- Huashan Shi
- Zhu Yuan
- Xiaolan Su
- Wen Zhu
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: November 1, 2012 https://doi.org/10.3892/ijmm.2012.1171
Pages: 33-42

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is one of the most effective antitumor drugs for non-small cell lung carcinoma (NSCLC) patients. However, its efficacy has encountered a plateau due to its side effects and drug resistance. Inducible nitric oxide (NO) synthase (iNOS) gene therapy has been reported to have antitumor effects in several types of cancers and enhances sensitivity to cisplatin, but the effects of iNOS gene therapy alone or its combination with cisplatin in lung cancer remain unclear. In the current study, we evaluated the effects of cationic liposome (LP)-mediated iNOS gene transfection on enhancing low-dose cisplatin-mediated antitumor effects in the A549 human lung adenocarcinoma cell line in vitro. Furthermore, we examined whether iNOS gene therapy enhances the antitumor effects of low-dose cisplatin in two A549 human lung cancer cell xenograft mouse models. The results revealed that iNOS gene therapy may significantly enhance low-dose cisplatin-mediated inhibition of cell proliferation, invasion, migration and promotion of cell apoptosis in A549 cells. Intratumoral administration of the LP-pVAX-iNOS complex significantly enhanced low-dose cisplatin-mediated suppression of subcutaneous tumor growth. Moreover, intravenous injection of the LP-pVAX-iNOS complex greatly enhanced low-dose cisplatin-mediated inhibition of experimental lung metastasis and prolonged the life span of mice without significant organ-related toxicity in a nude mouse model of lung metastasis compared to the cisplatin alone-treated group. Furthermore, iNOS gene-mediated enhancement of cisplatin-mediated antitumor effects in lung cancer may be related to the attenuation of p-mTOR, MMP2 and the activation of p-p53. Thus, the combination treatment with iNOS gene therapy and cisplatin may be a novel and effective therapeutic strategy for lung cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
2	Jamieson ER and Lippard SJ: Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev. 99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Adjei AA and Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest. 130:1211–1219. 2006. View Article : Google Scholar : PubMed/NCBI
4	Xie K and Fidler IJ: Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:55–75. 1998. View Article : Google Scholar : PubMed/NCBI
5	Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, Troso T and Nathan C: Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 256:225–228. 1992. View Article : Google Scholar : PubMed/NCBI
6	Heller A: Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. ChemMedChem. 3:1493–1499. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lala PK and Chakraborty C: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 3:149–156. 2001. View Article : Google Scholar : PubMed/NCBI
8	Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res. 88:1190–1198. 1997. View Article : Google Scholar : PubMed/NCBI
9	Puhakka A, Kinnula V, Näpänkangas U, Säily M, Koistinen P, Pääkkö P and Soini Y: High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS. 111:1137–1146. 2003. View Article : Google Scholar : PubMed/NCBI
10	Fitzpatrick B, Mehibel M, Cowen RL and Stratford IJ: iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide. 19:217–224. 2008. View Article : Google Scholar : PubMed/NCBI
11	Khare PD, Shao-Xi L and Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita Y and Kuroki M: Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res. 61:370–375. 2001.
12	Xu W, Liu L and Charles IG: Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J. 16:213–215. 2002.PubMed/NCBI
13	Soler MN, Bobé P, Benihoud K, Lemaire G, Roos BA and Lausson S: Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med. 2:344–352. 2000. View Article : Google Scholar : PubMed/NCBI
14	Lumniczky K and Safrany G: Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol Oncol Res. 12:118–124. 2006. View Article : Google Scholar : PubMed/NCBI
15	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ropponen KM, Kellokoski JK, Lipponen PK, Eskelinen MJ, Alanne L, Alhava EM and Kosma VM: Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol. 35:1204–1211. 2000. View Article : Google Scholar : PubMed/NCBI
17	Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A and Taddei GL: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol. 92:806–812. 2004. View Article : Google Scholar : PubMed/NCBI
18	Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T and Hirst DG: Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med. 11:160–168. 2009. View Article : Google Scholar : PubMed/NCBI
19	Worthington J, McCarthy HO, Barrett E, Adams C, Robson T and Hirst DG: Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med. 6:673–680. 2004. View Article : Google Scholar : PubMed/NCBI
20	Worthington J, Robson T, O’Keeffe M and Hirst DG: Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther. 9:263–269. 2002. View Article : Google Scholar : PubMed/NCBI
21	McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG and Robson T: p21 (WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther. 14:246–255. 2007. View Article : Google Scholar
22	Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S and Hirst DG: The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther. 15:495–503. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR and Blumberg D: Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res. 64:1386–1395. 2004. View Article : Google Scholar : PubMed/NCBI
24	Evig CB, Kelley EE, Weydert CJ, Chu Y, Buettner GR and Burns CP: Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide. 10:119–129. 2004. View Article : Google Scholar
25	Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, DeGraff W, Gamson J, Vodovotz Y, Russo A and Mitchell JB: Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide. 1:88–94. 1997. View Article : Google Scholar : PubMed/NCBI
26	Son KK and Hall KJ: Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther. 7:1324–1328. 2000.PubMed/NCBI
27	Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko L and Korolev AM: Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide. 8:59–64. 2003. View Article : Google Scholar : PubMed/NCBI
28	Chen JH, Lin HH, Chiang TA, Hsu JD, Ho HH, Lee YC and Wang CJ: Gaseous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion, and metastasis via iNOS-mediated MMP-2 production. Toxicol Sci. 106:364–375. 2008. View Article : Google Scholar : PubMed/NCBI
29	Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC and Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 62:6850–6856. 2002.PubMed/NCBI
30	Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 145:17–25. 2010. View Article : Google Scholar : PubMed/NCBI
31	Shamimi-Noori S, Yeow W-S, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, et al: Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther. 15:356–370. 2008. View Article : Google Scholar
32	Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC, et al: Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 11:733–739. 2004. View Article : Google Scholar
33	Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 6:1160–1166. 2000. View Article : Google Scholar : PubMed/NCBI
34	Fraser M, Chan SL, Chan SS, Fiscus RR and Tsang BK: Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene. 25:2203–2212. 2006. View Article : Google Scholar : PubMed/NCBI
35	Nguyen DM, Spitz FR, Yen N, Cristiano RJ and Roth JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 112:1372–1377. 1996. View Article : Google Scholar : PubMed/NCBI
36	Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR and Blumberg D: Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res. 64:8015–8021. 2004. View Article : Google Scholar : PubMed/NCBI
37	Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
38	Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007. View Article : Google Scholar : PubMed/NCBI
39	Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, et al: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 15:5404–5413. 2009. View Article : Google Scholar : PubMed/NCBI
40	Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD and Pavlakis GN: Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 15:647–652. 1997. View Article : Google Scholar : PubMed/NCBI
41	Keshamouni V, Arenberg D and Kalemkeriam G: Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. Springer; New York: pp. 1–395. 2009
42	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–23. 2007. View Article : Google Scholar
43	Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR and Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer. 81:889–896. 1999. View Article : Google Scholar : PubMed/NCBI
44	Obara H and Harasawa R: Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 72:869–874. 2010. View Article : Google Scholar : PubMed/NCBI
45	Bjorklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
46	Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C and Dorigo O: Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken). 67:535–544. 2010.
47	Urso L, Muscella A, Calabriso N, Vetrugno C, Jiménez E, Montiel M and Marsigliante S: Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells. Biochem Pharmacol. 79:810–816. 2010. View Article : Google Scholar : PubMed/NCBI
48	Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD and Wink DA: Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide. 19:73–76. 2008. View Article : Google Scholar : PubMed/NCBI